The symptom experience of patients during chemoradiation for head and neck cancer: a retrospective chart review

2021 ◽  
Vol 22 (3) ◽  
Author(s):  
Pauline Rose ◽  
Jamie Feldman ◽  
Erin Kelly ◽  
Bena Brown
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Symptom Experience

Symptom experience and regaining normality in the first year following a diagnosis of head and neck cancer: A qualitative longitudinal study

2012 ◽  
Vol 10 (3) ◽  
pp. 197-204 ◽  
Author(s):  
Alex Molassiotis ◽  
Margaret Rogers
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
First Year ◽  
Symptom Experience ◽  
Taste Changes ◽  
Symptom Experiences ◽  
One Year

AbstractIntroduction:Symptom experiences and their interference with life are not well-researched in head and neck cancer patients. The aim of the study was to explore and understand the experience of receiving treatment for head and neck cancer with particular focus on symptom experiences over a one year period from diagnosis.Methods:A qualitative study design was used with a heterogeneous sample of 16 patients with head and neck cancer. Interviews, conducted at four time points over 12 months, provided a total of 50 interview datasets.Results:Key themes derived include nutritional concerns, tiredness, and experiences related to the radiotherapy mask and regaining normality. These data highlight issues of importance in the first year of living with head and neck cancer: impact of nutritional changes on the lives of patients, including weight loss, dysphagia, xerostomia and taste changes; debilitation from ongoing fatigue; unpreparedness for and distress from the radiotherapy mask; and attempts to maintain a normal life amidst the interference of symptoms.Conclusion:Multitude of symptoms impact the patients' life, particularly nutritional symptoms and fatigue, and interfere with the patients' survivorship and quality of life. The changing nature of symptoms over the first year from diagnosis in head and neck cancer patients and the identified issues in the attempt to normalize their lives need to be incorporated more fully into the supportive care of head and neck cancer patients in order to improve their experience and enhance their survivorship.

Response to “Comorbidities in head and neck cancer: Agreement between self-report and chart review” by Vinidh Paleri

2007 ◽  
Vol 137 (6) ◽  
pp. 986-986
Author(s):  
Jeffrey E. Terrell ◽  
Sonia A. Duffy ◽  
Shraddha S. Mukerji
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Chart Review ◽  
Self Report

Perceived Symptom Experience in Head and Neck Cancer Patients with Lymphedema

2016 ◽  
Vol 19 (12) ◽  
pp. 1267-1274 ◽  
Author(s):  
Jie Deng ◽  
Sheila Ridner ◽  
Russell Rothman ◽  
Barbara Murphy ◽  
Kerry Sherman ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Symptom Experience

scholarly journals Effectiveness of Nerve Blocks for Management of Head and Neck Cancer Associated Neuropathic Pain Disorders; a Retrospective Study

2020 ◽  
Vol 6 (2) ◽  
Author(s):  
Khawaja Shehryar Nasir ◽  
Haroon Hafeez ◽  
Arif Jamshed ◽  
Raza Hussain
Keyword(s):  
Neuropathic Pain ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Pain Score ◽  
Nerve Block ◽  
Neck Cancer ◽  
Retrospective Chart Review ◽  
Research Centre ◽  
Fisher Exact Test ◽  
Nerve Blocks

Introduction: A portion of patients with head and neck cancer (HNC)-associated pain may not experience relief in symptoms with non-invasive modalities. A nerve block is a procedure in which a local anesthetic agent is injected along the nerve track to preferentially block sensory transmission. The literature on the effectiveness of nerve blocks in the management of HNC-related pain is limited. The purpose of this study was to determine the effectiveness of nerve blocks in management of breakthrough HNC-associated trigeminal or cervical neuropathic pain disorders. Materials and Methods: A retrospective chart review of patients who underwent a nerve block or infiltration procedure in the regions of head and neck for management of breakthrough HNC-associated trigeminal or cervical neuropathic pain disorders in the Orofacial Pain Medicine clinic, Shaukat Khanum Memorial Cancer Hospital and Research Centre, between November 2018 and November 2019 was completed. Information regarding demographics, diagnosis, and pain characteristics was extracted and reviewed. The Fisher-exact test and Mann-Whitney U test were used for analysis between independent and dependent variables. Results: A total of 27 participants were included in the investigation, of which 66.7 % were males. The average pre-procedure pain score was 6.85 ± 2.54. Following intervention, 81.5 % of the participants experienced greater than 75 % relief in pain for longer than 48 hours. The mean immediate post-procedure pain score was 0.26 ± 1.02 and the average duration of relief was 6.10 ± 6.50 weeks. The significant effect of nerve blocks was found to be statistically associated with the concurrent use of amitriptyline (p = 0.017). Conclusion: Nerve blocks, as an adjunctive therapy to pharmacologic treatment, can provide significant relief to patients with breakthrough HNC-associated trigeminal and cervical neuropathic pain disorders. However, the duration of relief experienced by the participants is inconsistent. The beneficial effect of nerve blocks appears to be more common in patients that were concurrently using amitriptyline.

Retrospective analysis of the incidence and severity of acute kidney injury (AKI) in patients with head and neck cancer receiving weekly cisplatin with radiotherapy (RAISe-AKI)

2020 ◽  
pp. 107815522097845
Author(s):  
Stephen J Dierckes ◽  
Morgan E Ragsdale ◽  
Monica R Macik ◽  
Kellie J Weddle
Keyword(s):  
Head And Neck Cancer ◽  
Adverse Events ◽  
Head And Neck ◽  
Retrospective Analysis ◽  
Neck Cancer ◽  
Low Dose ◽  
Small Sample Size ◽  
Retrospective Chart Review ◽  
Small Sample ◽  
Weekly Cisplatin

Introduction Low-dose, weekly cisplatin (40 mg/m2) regimens are currently utilized at Eskenazi Health in Indianapolis, Indiana for the treatment of head and neck cancer due to enhanced tolerability. This retrospective analysis analyzes the incidence, severity, and risk factors for AKI in patients who received this regimen. Methods A retrospective chart review was conducted including patients with head and neck cancer treated with weekly, low dose cisplatin (40 mg/m2) with concurrent radiotherapy (RT). From this criteria, 22 patients were identified and included in the final analysis. AKI was defined by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Results Of the 22 patients included, 12 (54.5%) experienced AKI, with 10 patients (45.5%) experiencing grade 1 AKI and 2 patients (9.1%) experiencing grade 2 AKI. Six patients (27.3%) required dose adjustments or delays due to renal adverse events, all of which had initial cisplatin total weekly doses of >70 mg. Those receiving a total weekly cisplatin dose of >70 mg were found to have a higher risk of developing an episode of AKI compared to the group receiving <70 mg (p = 0.029). Conclusion This analysis showed patients receiving weekly doses >70 mg of cisplatin as their initial treatment dose for head and neck cancer were more likely to experience AKI. There are inconsistencies in the frequency of AKI in our study compared to published literature; however, this comparison is difficult due to the small sample size of our trial. This demonstrates the need for further investigation into the issue.

Comorbidities in head and neck cancer: Agreement between self-report and chart review

2007 ◽  
Vol 136 (4) ◽  
pp. 536-542 ◽  
Author(s):  
Shraddha S. Mukerji ◽  
Sonia A. Duffy ◽  
Karen E. Fowler ◽  
Mumtaz Khan ◽  
David L. Ronis ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Chart Review ◽  
Self Report

scholarly journals Diagnostic-To-Treatment Interval and Disease Progression among Head and Neck Cancer Patients Undergoing Surgery

2017 ◽  
Vol 32 (1) ◽  
pp. 33-36
Author(s):  
Gerard F. Lapiña ◽  
Samantha S. Castañeda
Keyword(s):  
Head And Neck Cancer ◽  
Tumor Progression ◽  
Head And Neck ◽  
Disease Progression ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Retrospective Chart Review ◽  
Treatment Delay ◽  
Treatment Interval ◽  
Number Of Patients

Objectives: To determine whether the interval from pathological diagnosis to treatment is significantly delayed, and the presence or absence of disease progression occurring in those with, and without treatment delay, among head and neck cancer patients in our institution. Methods: Study Design:            Retrospective Chart Review Setting:                       Tertiary Government Hospital Subjects: Medical records of 70 patients with newly diagnosed head and neck cancer who underwent primary surgery from January 2011 to December 2015 were retrieved and available data were extracted.  Results:  A total of 28 patients were included in this study.  Majority of the cancers were in the larynx (42.9%) and oral cavity (42.9%).  The mean diagnostic-to-treatment interval (DTI) was 54 days, but 5(17.8%) out of the 28 had a DTI of more than 60 days. Four (80%) with a DTI more than 60 days had an upstage during surgery while 4 (17.4%) patients with DTI less than or equal to 60 days also had an upstage. 2 (60%) patients with treatment delay had tumor progression compared to 5 (21.7%) of those without treatment delay.  Only 1 (20%) out of the 5 patients with treatment delay had increased nodal metastasis in contrast to 8 (34.8%) of those who did not have treatment delay. Conclusion:  A number of patients undergoing surgery in our institution experienced delay to initiate treatment of more than 60 days and majority of these patients were noted to have disease progression. However, even patients with treatment prior to 60 days had increases in tumor stage, which may suggest that the interval aimed for should be shorter than 60 days. Keywords: head and neck cancer, treatment delay, diagnostic interval, tumor progression

Improve optimal treatment in head and neck cancer patients (HNCA).

2014 ◽  
Vol 32 (30_suppl) ◽  
pp. 227-227
Author(s):  
Glenn Morris Mills ◽  
Rebecca L. DeKay ◽  
Srinivas S. Devarakonda ◽  
Jennifer Nicholson ◽  
Lee Ann Maranto ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Creatinine Clearance ◽  
Head And Neck ◽  
Neck Cancer ◽  
Chart Review ◽  
Speech Pathology ◽  
Post Intervention ◽  
Pareto Chart ◽  
Peg Tube ◽  
Practitioner Education

227 Background: Since 2011, 50% of HNCA patients receiving concurrent chemoradiation with Cisplatin (CIS/XRT) have not been able to complete their therapy per protocol (dose over time interval) leading to suboptimal therapy. Based on historical data, the non-completion rate for patients HNCA receiving radiation/ high dose Cisplatin was 15%. We aim to improve this in our patients. Methods: A chart review of patients on CIS/XRT conducted and, using a Pareto Chart, the data indicated Acute Kidney Iinjury as the major cause for failure of completion. Using methodology from ASCO’s Quality Training Program, a process map for patients on treatment was created and an Ishikawa diagram (cause and effect) assisted in pinpointing breaks in processes. A telephone survey of surviving patients further clarified inadequacies. Using the Plan, Do, Study, Act (PDSA) improvement cycle, inadequacies were identified. Results: Chart review showed that significant side effects from treatment began around the 2nd cycle of Cisplatin in spite of adequate IV hydration following chemotherapy. Inadequate documentation of dietary and speech pathology consultations, patient weight and serum creatinine levels during treatment were noted. Patients reported minimal PEG tube education and infrequent use of PEG tube for hydration. Analysis of post treatment weight and creatinine level revealed a significant change in creatinine clearance. Checking daily weights, speech pathology and dietary consult prior to initiation of therapy, added hydration instructions to EPIC PEG tube instruction sheet, and nurse practitioner education and follow-up in symptom management clinic were part of the PDSA cycle interventions. If 2lb. weight loss, patients were brought in for repeat lab and IV hydration. Conclusions: Patients with advanced head and neck cancer are frail and subject to acute toxicity from chemotherapy. Change in Creatinine Clearance is a sensitive measure of renal damage/likely predictor of non-completion. Post-intervention patients had fewer unplanned admissions leading to lower costs. PDSA helped identify inadequacies in our education and monitoring processes. More post intervention data are needed to determine if true improvement in patient outcomes exist.

Sign in / Sign up

Export Citation Format

Share Document